Literature DB >> 27043788

Assessing the Diagnostic Properties of a Graded Oral Provocation Challenge for the Diagnosis of Immediate and Nonimmediate Reactions to Amoxicillin in Children.

Christopher Mill1, Marie-Noël Primeau2, Elaine Medoff2, Christine Lejtenyi2, Andrew O'Keefe3, Elena Netchiporouk4, Alizee Dery1, Moshe Ben-Shoshan5.   

Abstract

IMPORTANCE: The diagnostic properties of a graded provocation challenge (PC) among children presenting with a rash in the course of amoxicillin treatment are currently unknown.
OBJECTIVE: To assess the accuracy and the negative predictive value of the PC in a cohort of children referred with suspected allergy to amoxicillin. DESIGN, SETTING, AND PARTICIPANTS: A cohort study was conducted between March 1, 2012, and April 1, 2015, at the allergy clinic of the Montreal Children's Hospital, Montreal, Quebec, Canada. All children referred with suspected allergy to amoxicillin were approached. In addition, 346 eligible children were followed up to assess reactions to subsequent use of amoxicillin at the time of illness in cases with negative PC results. Data were collected on clinical characteristics, suspected antibiotic exposure, personal and first-degree relatives' comorbidities, and history of atopy and management of the reaction. Univariate and multivariate logistic regressions were compared to determine factors associated with immediate and nonimmediate reactions to the PC.
INTERVENTIONS: All children had a graded PC. MAIN OUTCOMES AND MEASURES: Reactions to the graded PC, the negative predictive value of the PC for nonimmediate reactions, and factors associated with immediate and nonimmediate reactions to the PC.
RESULTS: A total of 818 children were assessed (median age, 1.7 years [interquartile range, 1.0-3.9 years]; 441 [53.9%] male). Among all participants, 770 (94.1%) tolerated the PC, 17 (2.1%) developed mild immediate reactions, and 31 (3.8%) developed nonimmediate reactions. The graded PC had a specificity of 100.0% (95% CI, 90.9%-100.0%), a negative predictive value of 89.1% (95% CI, 77.1%-95.5%), and a positive predictive value of 100.0% (95% CI, 86.3%-100.0%). Among all 346 participants eligible for annual follow-up, 250 (72.3%; 95% CI, 67.2%-76.8%) responded, 55 of whom received subsequent full treatment with amoxicillin; 49 of these 55 participants (89.1%) reported tolerance to subsequent full treatment with amoxicillin, while 6 (10.9%) developed nonimmediate cutaneous reactions. History of a reaction occurring within 5 minutes of exposure was associated with immediate reactions to the PC (adjusted odds ratio = 9.6; 95% CI, 1.5-64.0), while a rash that lasted longer than 7 days (adjusted odds ratio = 4.8; 95% CI, 1.4-16.4) and parental history of drug allergy (adjusted odds ratio = 3.0; 95% CI, 1.3-6.8) were associated with nonimmediate reactions to the PC. CONCLUSIONS AND RELEVANCE: Graded PCs provide an accurate and safe confirmatory test for skin-related reactions to amoxicillin. Further studies are required to assess factors associated with the PC outcome groups.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27043788     DOI: 10.1001/jamapediatrics.2016.0033

Source DB:  PubMed          Journal:  JAMA Pediatr        ISSN: 2168-6203            Impact factor:   16.193


  42 in total

Review 1.  Antibiotic Allergy in Pediatrics.

Authors:  Allison Eaddy Norton; Katherine Konvinse; Elizabeth J Phillips; Ana Dioun Broyles
Journal:  Pediatrics       Date:  2018-05       Impact factor: 7.124

Review 2.  Controversies in Drug Allergy: Drug Allergy Pathways.

Authors:  Anca M Chiriac; Aleena Banerji; Rebecca S Gruchalla; Bernard Y H Thong; Paige Wickner; Paul-Michel Mertes; Ingrid Terreehorst; Kimberly G Blumenthal
Journal:  J Allergy Clin Immunol Pract       Date:  2018-12-17

Review 3.  Controversies in drug allergy: Testing for delayed reactions.

Authors:  Elizabeth J Phillips; Paul Bigliardi; Andreas J Bircher; Ana Broyles; Yoon-Seok Chang; Wen-Hung Chung; Rannakoe Lehloenya; Maja Mockenhaupt; Jonny Peter; Munir Pirmohamed; Jean-Claude Roujeau; Neil H Shear; Luciana Kase Tanno; Jason Trubiano; Rocco Valluzzi; Annick Barbaud
Journal:  J Allergy Clin Immunol       Date:  2018-12-17       Impact factor: 10.793

4.  The Cost of Penicillin Allergy Evaluation.

Authors:  Kimberly G Blumenthal; Yu Li; Aleena Banerji; Brian J Yun; Aidan A Long; Rochelle P Walensky
Journal:  J Allergy Clin Immunol Pract       Date:  2017-09-22

5.  The Impact of a Reported Penicillin Allergy on Surgical Site Infection Risk.

Authors:  Kimberly G Blumenthal; Erin E Ryan; Yu Li; Hang Lee; James L Kuhlen; Erica S Shenoy
Journal:  Clin Infect Dis       Date:  2018-01-18       Impact factor: 9.079

6.  Penicillin Allergy Testing Is Cost-Saving: An Economic Evaluation Study.

Authors:  Bernardo Sousa-Pinto; Kimberly G Blumenthal; Eric Macy; Ana Margarida Pereira; Luís Filipe Azevedo; Luís Delgado; João Almeida Fonseca
Journal:  Clin Infect Dis       Date:  2021-03-15       Impact factor: 9.079

Review 7.  Diagnosing and managing drug allergy.

Authors:  Elissa M Abrams; David A Khan
Journal:  CMAJ       Date:  2018-04-30       Impact factor: 8.262

Review 8.  Addressing Inpatient Beta-Lactam Allergies: A Multihospital Implementation.

Authors:  Kimberly G Blumenthal; Erica S Shenoy; Anna R Wolfson; David N Berkowitz; Victoria A Carballo; Diana S Balekian; Kathleen A Marquis; Ramy Elshaboury; Ronak G Gandhi; Praveen Meka; David W Kubiak; Jennifer Catella; Barbara B Lambl; Joyce T Hsu; Monique M Freeley; Alana Gruszecki; Paige G Wickner
Journal:  J Allergy Clin Immunol Pract       Date:  2017 May - Jun

Review 9.  The role of a clinical pharmacist in spurious Penicillin allergy: a narrative review.

Authors:  Rashmeet Bhogal; Abid Hussain; Ariyur Balaji; William H Bermingham; John F Marriott; Mamidipudi T Krishna
Journal:  Int J Clin Pharm       Date:  2021-01-13

10.  The Penicillin Allergy Delabeling Program: A Multicenter Whole-of-Hospital Health Services Intervention and Comparative Effectiveness Study.

Authors:  Kyra Y L Chua; Sara Vogrin; Susan Bury; Abby Douglas; Natasha E Holmes; Nixon Tan; Natasha K Brusco; Rebecca Hall; Belinda Lambros; Jacinta Lean; Wendy Stevenson; Misha Devchand; Kent Garrett; Karin Thursky; M Lindsay Grayson; Monica A Slavin; Elizabeth J Phillips; Jason A Trubiano
Journal:  Clin Infect Dis       Date:  2021-08-02       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.